MUDr. I. Cierna Peterova s.r.o.

At MUDr. I. Cierna Peterova s.r.o., investigators are evaluating new treatments to improve asthma control, reduce exacerbations, and enhance lung function for patients whose disease remains inadequately managed.

• High‑dose inhaled corticosteroid and long‑acting bronchodilator combinations
• Triple‑therapy metered‑dose inhaler (budesonide/glycopyrronium/formoterol)
• Anti‑TSLP antibody dose‑finding study
• Eosinophil‑targeted therapy for severe disease

The site’s multidisciplinary team of seven investigators contributes to a growing portfolio of trials, offering patients access to innovative options while generating data that may shape future asthma guidelines.

Clinical work at the Brandýs‑Nad‑Labem facility focuses on chronic obstructive pulmonary disease (COPD), aiming to lessen exacerbations and improve daily breathing capacity through novel pharmacologic approaches.

• Fixed‑dose triple combination versus dual therapy
• Inhaled phosphodiesterase‑4 inhibitor CHF6001 as add‑on to triple therapy
• Tezepelumab evaluation for moderate‑to‑very severe COPD
• Verekitug to reduce COPD exacerbation rates

With twelve active studies, the centre provides a platform for patients to receive emerging therapies while supporting the generation of evidence for better COPD management.

Researchers are investigating therapies for persistent cough that does not respond to standard treatment, targeting reductions in cough frequency and improving quality of life for individuals with refractory or unexplained symptoms.

• BLU‑5937 assessment for refractory and unexplained chronic cough
• Objective measurement of 24‑hour cough frequency
• Validation of patient‑reported outcome tools for cough severity
• Exploration of cough reflex pathways as therapeutic targets

The clinic’s expertise in respiratory diagnostics enables precise enrollment and monitoring, offering participants access to cutting‑edge interventions for a condition that often lacks effective options.

Across asthma, COPD, and chronic cough, the site conducts comprehensive studies that combine lung‑function testing, biomarker analysis, and digital inhaler technology to refine treatment selection and safety monitoring.

• Cross‑disease evaluation of inhaled therapies on lung function
• Biomarker‑driven patient stratification, including FeNO measurement
• Assessment of electronic inhaler modules for adherence and outcomes
• Safety profiling of novel biologics in diverse respiratory populations

By integrating multiple therapeutic areas, the facility advances a holistic understanding of respiratory health, supporting both patient care and the broader scientific community.